Listed

Sutro Biopharma, Inc.: Form 10-K for the period ended Dec 31, 2021

Filed with the SEC on Feb 28, 2022 and accepted by EDGAR at Feb 28, 2022, 16:32 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2021-01-01 to 2021-12-31$61.9mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development12 months2021-01-01 to 2021-12-31$104.4mus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2021-01-01 to 2021-12-31−$98.5mus-gaap:OperatingIncomeLoss
Income tax12 months2021-01-01 to 2021-12-31$0us-gaap:IncomeTaxExpenseBenefit
Net income12 months2021-01-01 to 2021-12-31−$105.5mus-gaap:NetIncomeLoss
Operating cash flow12 months2021-01-01 to 2021-12-31−$81.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Share repurchases12 months2021-01-01 to 2021-12-31$7.0kus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2021-12-31$30.4mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-12-31$218.5mus-gaap:AssetsCurrent
Total assetsAt period end2021-12-31$341.4mus-gaap:Assets
Current liabilitiesAt period end2021-12-31$41.7mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-12-31$88.8mus-gaap:Liabilities
Long-term debtAt period end2021-12-31$15.7mus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2021-12-31$9.4mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2021-12-31$252.6mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000950170-22-002312. Last ingested by Listed: Oct 24, 2026, 15:12 ET. Listed shows no prices and gives no investment advice.